Intellia THERAPEUTICS

Intellia Therapeutics Corporate Responsibility Report

Publication date: May 2023

TABLE OF CONTENTS

Our Corporate Responsibility Commitment

About Intellia

Commitment to Patients

Commitment to Our Employees

Commitment to Our Environment and Local Communities

Commitment to Information Security

Commitment to Corporate Governance

Intellia Awards

Contact Information

SASB Reporting

Legal Disclaimer

All data presented in this report are for the year ended December 31, 2022, unless noted otherwise.

Our Corporate Responsibility Commitment

Intellia's objective is to build a sustainable company delivering on our commitment to the patients we serve, our employees, community, environment and shareholders.

We believe Environmental, Social and Governance (ESG) principles support long-term value creation. Throughout this report, we have highlighted our approach to managing risk and taking advantage of opportunities in key ESG areas — the areas that are most relevant to the long-term sustainability of our company.

About **Intellia**

About Intellia

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.

Our focus is on developing CRISPR-based therapies to treat patients with genetic diseases, cancer and autoimmune conditions. Our work is not only important for the patients living with these often debilitating and life-threatening diseases, but also for the families, friends and caregivers who provide their invaluable support.

At Intellia, our team of dedicated scientists work tirelessly to harness our proprietary genome editing technology for human therapeutic use—technology enabled by the pioneering work of Drs. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier, co-recipients of the 2020 Nobel Prize in Chemistry.

As part of our core strategy, we are employing a modular technology platform allowing us to leverage the learnings from one program to the next and advance a diverse and growing pipeline of both *in vivo* and *ex vivo* investigational therapies.

We hope to change the future of medicine with our CRISPR-based therapies.

Intellia is Leading a New Era in Medicine

FIRST AND ONLY COMPANY
to demonstrate successful systemic CRISPR gene editing in humans

3
CLINICAL PROGRAMS
achieved human proof-of-concept:
- NTLA-2001
- NTLA-2002
- SCD*

EXTENSIVE R&D
$880M+
spent in the last 5 years

50+
patients have been dosed with Intellia's *in vivo* CRISPR-based therapies in ongoing clinical trials, with durability data beyond one year in the earliest patients

10+
in vivo and *ex vivo* programs for diseases with high unmet need**

6
collaborations with leading biotech and pharma partners

BROADEST AND DEEPEST GENOME EDITING TOOLBOX
underpins platform innovation and research engine

* Novartis-led sickle cell disease (SCD) program that utilized Intellia's *ex vivo* genome editing technology.
** Both wholly owned and partnered programs.

Intellia THERAPEUTICS

Intellia's Core Values

Our values are at the heart of our company's identity and culture.

ONE

One is respect for individuals and our unique qualities, strengths and experiences; our own ways to understand, learn and improve. **One** is our single-minded determination to excel and to succeed together. **One** is trust and relying on every one of us to triumph.

DISRUPT

Disrupt by thinking courageously to create a better future. **Disrupt** by defying conformity and interrogating the status quo. **Disrupt** with challenging thoughts and using skepticism and imagination to develop innovative solutions.

EXPLORE

Explore because we seek new ways to tackle disease. **Explore** to open our minds to be free from assumptions and be open to new ideas. **Explore** by staying curious and pushing boundaries. **Explore** means thinking of new ways to overcome obstacles.

DELIVER

Deliver by focusing on the objective and your determination to complete the task. **Deliver** by advancing relentlessly and by maintaining high standards. **Deliver** by staying accountable and pulling your weight. **Deliver** because patients are counting on us to make the promise a reality.

Intellia THERAPEUTICS

Commitment to **Patients**

Commitment to Patients

Every day, more than 600* team members come to work at Intellia. We are motivated by our mission to develop potentially curative genome editing treatments for people living with severe diseases. Conventional medicines treat the symptoms instead of the cause of conditions, meaning that patients must be treated throughout their lives. We are working to develop one-time treatments that target the root cause of disease.

"Many of us pursuing work in the biotechnology industry are inspired by the loss of a loved one or someone in our community who is living with a disease."

Intellia President and CEO
John Leonard, M.D.

Patients are counting on us

Nancy lives with transthyretin amyloidosis with polyneuropathy (ATTRv-PN).

Milton lives with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).



Shanna lives with hereditary angioedema (HAE).

** As of May 1, 2023*

Patient Stories

Meet Nancy, Shanna and Milton — all living with genetic diseases that drive us to do what we do every day. Their strength inspires us, energizes us and compels us to work urgently to address their unmet medical needs. Read their stories.

We are committed to ensuring the patient voice informs our research and development, by including:

- Patient focus groups
- Patient speakers at employee Town Halls
- Patient stories, photos and videos on our website and social media

Nancy, living with ATTRv-PN

Shanna, living with HAE

Milton, living with ATTR-CM

Intellia THERAPEUTICS

Commitment to Patient Advocacy

We are proud to work closely with a number of leading patient organizations, so we can better understand the needs of patients, their families and caregivers. These relationships and collaborations allow us to hear the patient voice and help inform our decisions.

Here are some of the advocacy organizations we have relationships with who help support patients and raise awareness for ATTR and HAE:

AMYLOIDOSIS SUPPORT GROUPS
You Are Not Alone
www.amyloidosissupport.org

NZAPA

HAEi
HAE International

FAMY
NORRBOTTEN

Amyloidosis Research Consortium

HAEA
US HEREDITARY ANGIOEDEMA ASSOCIATION

Intellia THERAPEUTICS

Clinical Trial Principles and Data Transparency

Clinical trials are required to bring new treatments and therapies to market. These studies evaluate the effects of experimental treatments and help researchers to better understand the disease, as well as its diagnosis, prevention and potential treatment options.

Also, clinical trial data allow regulatory agencies to determine whether the drug or therapy is safe, effective and, ultimately, ready to be made available to the prescribing community.

Intellia is committed to transforming the lives of people with severe diseases by developing genome editing treatments. As part of this commitment, we are working to better understand the needs of the patient community and their families and caregivers. We would like to thank these individuals for participating in our clinical trials thus far.

Clinical Trial Data Disclosure

Intellia-sponsored clinical trials are registered on clinicaltrials.gov, a searchable database maintained by the U.S. National Institutes of Health. Our trials are also registered on the EU Clinical Trials Information System (CTIS) and comply with applicable laws and regulations.

Intellia is committed to making the results from our clinical trials available at appropriate time points through meeting registry posting requirements, peer-reviewed publications* and scientific presentations.

** Meeting the recommendations of the International Committee of Medical Journal Editors (ICMJE)*

Intellia THERAPEUTICS

Ethical Conduct and Diversity, Equity and Inclusion in Clinical Trial Studies

Ethics in Clinical Studies

At Intellia, we recognize the importance of medical research as part of the process for developing innovative medicines for patients. We are committed to conducting clinical trials in accordance with the highest ethical, scientific and safety standards to ensure we are protecting the rights and wellbeing of the individuals enrolled in our clinical trials.

All Intellia-sponsored clinical studies are designed and conducted to integrate ethical and safety procedures and protocols that meet or exceed all applicable local laws and regulations as well as global guidelines. Intellia has implemented and is maintaining quality assurance and quality control systems with written standard operating procedures to help ensure that trials are conducted and data are generated, documented and reported in compliance with the protocol, Good Clinical Practice standards defined by the International Conference on Harmonization (ICH) guidance, and the applicable regulatory requirements.

Clinical trial participants must provide informed consent before they are entered into a trial. Patients are provided an Institutional Review Board (IRB) or Ethics Committee (EC) approved Informed Consent Form that explains the details of the trial, including its possible risks and benefits. Participation in a clinical trial is always voluntary and participants may withdraw at any time and for any reason.

Diversity, Equity and Inclusion (DEI) in Clinical Trials

Our aim is to sponsor inclusive clinical trials that represent the diversity of the people living with the disease who may benefit from the treatment being developed, if it is approved. We recognize diverse populations may be impacted differently by the same disease or may have varying responses to the same treatment. We aim to work with communities to increase health literacy and awareness of clinical trials. We will build trusting relationships and collaborate with partners to improve access to our clinical research and investigational treatments. For ATTR amyloidosis and HAE, we are partnering closely with patient advocacy groups to engage with patients that represent the breadth of the population we aim to serve.

Current Clinical Trial Footprint

Intellia is conducting ongoing clinical trials for two investigational therapies:

- NTLA-2001 for Transthyretin (ATTR) Amyloidosis
- NTLA-2002 for Hereditary Angioedema (HAE)

DOSED >50 PATIENTS ACROSS BOTH FIRST-IN-HUMAN STUDIES

NTLA-2001

- Phase 1; NTC04601051
- Patient population included people living with hereditary ATTRv-PN and hereditary ATTRv-CM or wild-type cardiomyopathy (ATTRwt-CM), NYHA Class I - III
- Patients enrolled in New Zealand, United Kingdom, and select European countries
- Long-Term Follow-Up study will commence in 2023; NCT05697861

NTLA-2002

- Phase 1/2; NCT05120830
- Patient population included people with Type I or Type II HAE
- Phase 1 portion: Patients enrolled in New Zealand, United Kingdom and the Netherlands
- Phase 2 portion*: Patients currently enrolling in New Zealand and the Netherlands. Patients to be enrolled in additional countries.

* *Intellia FY'22 Earnings PR; Intellia NTLA-2002 IND Clearance PR*

Intellia THERAPEUTICS

Commitment to **Our Employees**

Commitment to Our Employees

Investing in our employees' professional career growth and personal wellbeing is an important priority at Intellia. We provide a wide range of learning opportunities that help our employees gain on-the-job experiences, learn through and with each other, and upskill through in-person, virtual and formal training programs.

We believe employees at all levels are leaders at Intellia

Leadership Competencies and Career Ladders are clearly defined to help our employees understand their individual career journey. We offer a variety of training programs that support our employees every step of the way. This starts with our New Employee Orientation Program, which provides new hires with the information they need to integrate and be successful. We offer Development and Career Days focused on education, learning new skills and showcasing different career paths. As part of these initiatives, programming is tailored to the topics of interest identified by employees. Internal job opportunities are highlighted to promote job mobility. Annually, our employees work with their managers to set professional development goals and an action plan. Our goal is to ensure employees have the necessary skills to meet their current responsibilities optimally, as well as develop new abilities for the future.

Fostering leadership is fundamental

We invest in developing the next wave of people managers at the company. Our Manager Orientation and Leadership Forums aim to refine managerial skills in the areas of coaching for performance, development planning and leadership.

Commitment to equitable pay

We are committed to equitable pay, irrespective of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status, and conduct routine comprehensive pay-equity analyses.

Intellia's Culture and Employee Highlights

Our Story	Team Members	Headquarters	Best Place to Work
	600+		
Learn more about who we are	Full-time employees	Cambridge, MA	Recognized by *The Boston Globe*, *BioSpace* and *Forbes*

Intellia THERAPEUTICS

Employee “Speak Up Line”

Intellia’s Anti-Retaliation and Whistleblower Policy is designed to protect employees and support Intellia’s commitment to integrity and ethical behavior.

At the core of Intellia’s values, we seek to foster a culture where employees feel comfortable with open, direct and honest communication with their managers and peers. In the event employees would prefer to report an incident anonymously, employees can call or email the “Speak Up Line” which Intellia has established for receipt of questions and concerns over any Intellia activity that may be inconsistent with any law, regulation, our policies or our Code of Business Conduct and Ethics.

The Speak Up Line is managed by a third-party required to maintain the anonymity of the caller if so requested. Any report or complaint received is reviewed and addressed in a timely manner. In addition, reports are provided to the Audit Committee of the Board of Directors on a quarterly basis.

Intellia THERAPEUTICS

Cultural Ambassadors

Many of our employees actively participate as an **Intellia Cultural Ambassador**, fostering a grassroots approach with support and guidance from our leadership team. We regularly get together to learn, help the greater Boston community, celebrate our diversity and get to know one another.

Our Cultural Ambassador programs aim to align our workforce around our core values and consist of the following themes: diversity, equity and inclusion, continuous learning, wellness and sustainability, social events and community outreach.

Cultural Ambassador Teams

- Community Events
- Diversity, Equity and Inclusion
- Learning and Engagement
- Wellness and Sustainability
- Social Events

Intellia THERAPEUTICS

Commitment to Our Employees – Benefits

90% of premiums covered through Blue Cross Blue Shield MA, 100% vision insurance

100% company-funded life insurance, short- and long-term disability through Sun Life

A competitive 401k match, FSA for dependents and free parking or a subsidy for your commute

Intellia employees enjoy:

- Company-sponsored social events
- Employee-led clubs and teams
- Family planning benefit
- Immigrant sponsorship
- Travel assistance
- Education assistance
- Employee Stock Purchase Plan (ESPP)
- Free drinks and snacks
- Quarterly on-site dental & vision services
- Tuition reimbursement
- Employee assistance program
- 401K match
- Free onsite gym
- Quarterly on-site financial advisor 1:1s
- Reproductive Health Program
- Pet Insurance
- Company-wide shutdowns

Intellia THERAPEUTICS

Diversity, Equity and Inclusion (DEI)

We're dedicated to championing a culture that celebrates diversity and fosters collaboration inside the organization and in our community.

Intellia's core values include working together as one with respect for individuals, our unique qualities, strengths and our own ways to understand, learn and improve. Through our partnerships, we can build key relationships in our community and help pave the way for those wanting to pursue a career in the biotechnology industry. We are committed to increasing representation of underrepresented minorities at Intellia, particularly in leadership roles. Our recruiting team underwent bias awareness training, and we have sponsored career fairs and conferences at organizations focused on underrepresented minorities to ensure we continue to attract the best talent and increase representation. Additionally, current Intellia employees are participating in unconscious bias training throughout the year.

PROGRAMS WE SPONSOR:

UNCF A mind is a terrible thing to waste®

SACNAS

MASSBAY STEM MENTOR PROGRAM

OUTbio

LATINOS IN BIO

Intellia THERAPEUTICS

Employee Resource Groups

OUTellia
INTELLIA'S LGTBQ+ EMPLOYEE RESOURCE GROUP

WORKING CAREGIVERS
Employee Resource Group

WISE
Women In Science & Engineering & Allies

In 2022, we expanded our DEI efforts with the launch of Employee Resource Groups (ERGs). ERGs are voluntary, employee-led groups focused on fostering a diverse, inclusive workplace aligned with ONE Intellia. They are led and participated in by employees who share a characteristic, whether it's gender, ethnicity, religious affiliation, lifestyle or interest. The groups exist to provide support and help in personal or career development, and to create a safe space where employees can bring their whole selves to the table. Allies are also invited to join the ERG to support their colleagues.

ERG Activities

- "Nice Girls Don't Get the Corner Office" Book Club
- Women's History Month Panel Discussion
- STEMatch Career Day for Boston Public Schools
- Women's Equality Day Awareness
- Pride Month Celebration
- Trevor Project Fundraiser
- Parenting in the Digital World
- Caregiver Reflections

Intellia THERAPEUTICS

Diversity of Our Senior and Executive VPs and Employees

SENIOR AND EXECUTIVE VPs



50%
Female



33%
Ethnically Diverse

EMPLOYEES



56%
Female

25+
Countries of Origin

We're up to date with our EEO-1 report and filed through Fiscal Year-End 2021.
We filed the report on May 20, 2022.

DEI data as of March 31, 2023.

Intellia THERAPEUTICS

Promoting the Employee Voice

We provide a multitude of ways to gather insights from our employees around what is important to them, what we can improve on and how we can continue to ensure Intellia is a great place to work.

Several Intellia initiatives have come out of this insight gathering, such as expanded family planning benefits, a formal peer-to-peer recognition program and refreshed leadership competencies by level.

The Results of Our Efforts

98%

of employees felt confident they made the **right decision to join Intellia**

95%

of employees said their job makes them feel like they are **part of something meaningful**

93%

of employees agreed that Intellia operates by **strong values**

Intellia THERAPEUTICS

Intellia's Employee Referral Program

Top talent attracts top talent. We designed our employee referral program to highlight the brilliant minds Intellia employees bring into the organization.

Referrals are and always will be our most valued source of hire.

#1

Source of Hire

Of the 7 sources of hire, "employee referral" is ranked #1

38% of new hires were introduced to the job opening by an employee referral

48% of employees submitted at least 1 referral applicant in 2022

1/1/2022 – 3/10/2023

Intellia THERAPEUTICS

Commitment to

Our Environment and Local Communities

Commitment to Our Environment and Local Communities

We take our responsibility as a member of our local community seriously. Through our Cultural Ambassadors Program and other initiatives, our employees volunteer to serve and fundraise for homeless shelters, community beautification projects and educational initiatives, particularly STEM mentoring initiatives in underserved communities. In addition, we have partnered with the United Negro College Fund and established an Intellia scholarship for college students from underrepresented groups pursuing life science majors.

Our **Wellness & Sustainability team** celebrates Earth Day annually to promote green initiatives and spread knowledge on how to live a green life.

Although, we currently have a small ecological footprint, we believe we can make a difference in protecting our environment. We invest in variable flow fume hoods, ENERGY STAR lab freezers, GreenPak™ pipette tips, recyclable batteries and fluorescent and LED bulbs.

Intellia THERAPEUTICS

Environmental Sustainability at Intellia

Energy Efficient Buildings

Reduction efforts with the installation of beverage machines that reduce or eliminate aluminum can or pod usage

Composting services and removal of plasticware

Recycling Programs

Single-stream recycling at our 2nd largest building

Dual-stream recycling at all other buildings

Transportation Benefits

Non-automobile transportation benefits

Access to electric vehicle charging stations

Intellia THERAPEUTICS

Sample of Intellia's Community Connections in 2022

Our employees frequently participate in a variety of community volunteering and donation programs.

10+

charitable organizations in 2022, with over **100** employees volunteering in various service projects

$40K+

corporate and employee donations to UNCF

350

science experiment kits were assembled to support girls looking to work in STEM careers

2

blood donation drives through Massachusetts General Hospital

20

students were hosted from The LEAH Project for a career panel, networking session and lab tour

Intellia THERAPEUTICS

Select Community Partnerships

Intellia employees volunteering
to pack STEM kits for Science Club for Girls

Community Volunteering

- The LEAH Project
- Science Club for Girls
- Waltham Fields Community Farm
- East End House Food Pantry
- Project Onramp
- Biomedical Science Careers Program
- CASPAR Emergency Services Center & Shelters
- Esplanade Association
- Fenway Victory Gardens

Intellia THERAPEUTICS

Commitment to
Information Security

Commitment to IT Security

Oversight, Accountability and Training

A Big Four accounting firm performed a cybersecurity maturity assessment in February 2023. We also have comprehensive penetration testing performed by a cyber consulting firm annually (last one performed September 2022).

The Board's Audit Committee is updated semi-annually on Intellia's cybersecurity program maturity and informed about incidents. The full Board is updated once a year on our overall cybersecurity program. Internally, the Risk Oversight and Compliance Committee (ROCC) assesses risk and compliance for Intellia. Cybersecurity maturity and incidents are discussed monthly with the IT Steering Committee.

New hires are required to attend cybersecurity training as part of their onboarding. We require annual cybersecurity training for all full-time users, consultants, contractors, service providers and other users who have access to Intellia systems.

Information Governance and Privacy

Intellia formed an Information Governance Group to ensure the proper handling of one of Intellia's most critical assets — our information. The Information Governance Group is led by our head of IT and routinely reports to ROCC. Our Data Classification Guidelines explain how to handle categories of information. In 2023, we continued to mature our Privacy Program by appointing a Global Privacy Officer and publishing a Global Privacy Policy.

Reducing Risks with Suppliers and Supply Chain

We strongly value our vendor relationships as we believe they have been a key factor in our long-term success. We established a Third-Party Risk Management Program, where we assess and monitor risks with new and existing vendors. As part of our commitment to continuous improvement, we also use industry-standard frameworks and tools when monitoring our suppliers for any risk profile changes.

Commitment to
Corporate Governance

Commitment to Corporate Governance

Good corporate governance is important to ensure Intellia is managed for the long-term benefit of our stockholders.

Our Code of Business Conduct and Ethics applies to all officers and employees. We have established committee charters for the Audit Committee, Nominating and Corporate Governance Committee, and Compensation and Talent Development Committee.

Board of Directors At-a-Glance

62 years Average age of Board member

5 years Average tenure on Intellia's Board



30% Female

10% Racial or ethnic diversity



9 of 10 Directors are independent

As of April 28, 2023

Intellia THERAPEUTICS

Board of Directors – Commitment to Diversity

We believe that diversity among directors, inclusive of race, ethnicity, sexual orientation and gender, as well as experience, is an important attribute of a well-functioning board of directors and a measure of sound corporate governance.

Our Second Amended and Restated Corporate Governance Guidelines to affirm our commitment to increasing our Board's diversity.

The Board of Directors includes the value of seeking diversity in considering whom to elect or nominate for membership in the Board of Directors. In evaluating director candidates, including directors eligible for reelection, the Committee shall consider such factors as character, integrity, judgment, diversity with respect to age, gender, ethnicity, race, nationality and sexual orientation, independence, skills, education, expertise, business acumen, business experience, length of service, understanding of the Company's business and industry, conflicts of interest and other commitments.

Our board racial/ethnic diversity is currently 10%. In an effort to further support our goal of increased board diversity, we will continue to recruit for open seats on the board of directors and have engaged a third-party search firm to help us identify and recruit qualified candidates with diverse characteristics ranging from age, disability, gender identity or expression, ethnicity, military veteran status, national origin, race, religion, sexual orientation, and other backgrounds and experiences.

Intellia THERAPEUTICS

Intellia Awards

©2021 FORBES MEDIA LLC. USED WITH PERMISSION

Forbes 2021

AMERICA'S BEST MID-SIZE COMPANIES

The Boston Globe

TOP PLACES TO WORK 2021

MASSACHUSETTS

2022 BEST PLACES to WORK

PRESENTED BY BioSpace

AWARD

POPULAR SCIENCE

BEST OF WHAT'S NEW 2021

WINNER

The Boston Globe

TOP PLACES TO WORK 2022

MASSACHUSETTS

2023 BEST PLACES to WORK

PRESENTED BY BioSpace

Intellia THERAPEUTICS

Contact Information

Corporate Headquarters

40 Erie Street
Cambridge, MA 02139

Investor contact
ircontact@intelliatx.com

Investor website
https://ir.intelliatx.com

SEC filings
https://ir.intelliatx.com/financial-information/sec-filings

Annual reports
https://ir.intelliatx.com/financial-information/annual-reports

Governance guidelines
https://ir.intelliatx.com/static-files/dca3f8f4-d606-42fb-afd5-36b3dffc1308

Clinical trial contact
clinicalscience@intelliatx.com

Careers page
https://www.intelliatx.com/careers/

SASB Reporting

SASB Reporting

The Sustainability Accounting Standards Board (SASB) framework aims to provide a comparable, consistent and transparent manner for communicating corporate disclosure of ESG factors. Here, we have reported Intellia's alignment to all metrics in the SASB biotechnology and pharmaceuticals framework.

SASB Topic/Code	Accounting Metric	Disclosure
HC-BP-210a. 1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	See page 12
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	None
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	None
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Not applicable – Intellia is a pre-commercial company
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Not applicable – Intellia is a pre-commercial company
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	None
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Not applicable – Intellia is a pre-commercial company
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not applicable – Intellia is a pre-commercial company

SASB Reporting

SASB Topic/Code	Accounting Metric	Disclosure
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Not applicable – Intellia is a pre-commercial company
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Not applicable – Intellia is a pre-commercial company
HC-BP-250a.3	Number of recalls issued, total unites recalled	Not applicable – Intellia is a pre-commercial company
HC-BP-250a.4	Total amount of product accepted for takeback, reuse or disposal	Not applicable – Intellia is a pre-commercial company
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	None
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Not applicable – Intellia is a pre-commercial company
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	Not applicable – Intellia is a pre-commercial company
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests and/or filing of criminal charges related to counterfeit products	Not applicable – Intellia is a pre-commercial company
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Not applicable; Any material legal proceedings are disclosed in Intellia's 10-K
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	Not applicable – Intellia is a pre-commercial company

Intellia THERAPEUTICS

SASB Reporting

SASB Topic/Code	Accounting Metric	Disclosure
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	See commitment to our employees
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Within the biotech industry standard
HC-BP-430a.1	Percentage of (1) entry's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	Not applicable
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	None. Any material legal proceedings are disclosed in Intellia's 10-K
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	See page 13. Intellia places value on compliance with law, honesty and integrity. Our interactions with health care professions are guided by these principles and incorporated into our daily practices.

SASB Topic/Code	Activity Metric	Disclosure
HC-BP-000.A	Number of patients treated	>50 patients dosed with investigational CRISPR-based therapies
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	See our pipeline

Intellia THERAPEUTICS

Forward-Looking Statements – Safe Harbor

This report contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding our beliefs and expectations about the advancement, expansion, modularity and acceleration of our CRISPR-based platform technology and our *in vivo* and *ex vivo* pipeline to develop genome editing therapies across a variety of indications; our ability to replicate or apply results achieved in preclinical or clinical studies in any future studies; our ability to ensure that our clinical trials are conducted in accordance with the highest ethical, scientific and safety standards and that data are generated, documented and reported in compliance with the protocol, Good Clinical Practice standards defined by the International Conference on Harmonization (ICH) guidance, and the applicable regulatory requirements; our ability to ensure the proper handling of Intellia's information and that our cybersecurity and privacy programs would prevent a breach involving our information; and our ability to recruit and retain employees and directors, including diverse employees and directors, to execute our long-term strategy. Any forward-looking statements in this report are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Intellia's most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission ("SEC"). All information in this report is as of the date of the report, and Intellia undertakes no duty to update this information unless required by law.

Intellia THERAPEUTICS

Intellia

THERAPEUTICS